In this issue of the Journal, Fudin et al. 1 visit the cost issue of parenteral opioids. Specifically, they compared the cost of a continuous subcutaneous infusion of hydromorphone to a continuous intravenous infusion of morphine and found that the hydromorphone infusion resulted in substantial savings. As part of this study, they performed a detailed analysis of not only the drug costs, but also the costs of associated supplies, pumps, line placements, etc. In a similar vein, Seamans, Wong, and Wilson 2 recently reported a cost comparison of systemic opioid treatment versus interventional pain therapy, including a neurolytic celiac plexus block and intraspinal opioids in a patient with intractable abdominal cancer pain. The intrathecal therapy was more effective and less costly. These two articles invoke both a scientific as well as an emotional response.
In a scientific sense, these articles provide a good opportunity to review the indications for the parenteral routes of opioid infusions. Approximately 5 to 10 percent of cancer patients with pain will have inadequate pain control with oral analgesics some time during the course of their disease. Indications for the continuous intravenous infusion of opioids include:
• Intolerance of intramuscular and oral routes;
• The need for frequent injections, more often than every two hours, for pain control;
• The presence of prominent bolus effects, such as sedation or the rapid return of pain after injections, on repetitive dosing; and
• The need for rapid titration to control severe, acute pain.
Subcutaneous infusions offer the following significant advantages over the use of intermittent subcutaneous, intramuscular, or intravenous routes:
• They avoid repetitive intramuscular or subcutaneous injections;
• They avoid the need for intravenous access;
• They free the patient from delay in the administration of opioid analgesic;
• They provide a continuous level of pain control with no peaklevel side effects or trough-level pain breakthrough;
• They are readily accepted and managed by patients and their families; and
• They allow earlier discharge home without compromising pain control.
Furthermore, as reported by Fudin et al., 1 hydromorphone is a better drug to use subcutaneously because higher doses can be administered in less volume than can be done in the case of morphine.
Finally, indications for the intraspinal route of opioid administration include:
• Opioid sensitive pain not managed by conventional routes because of dose-limiting side effects;
• Severe bilateral pain or midline pain below the level of the umbilicus; and
• Pelvic pain due to sacral bone metastasis or lumbosacral plexus involvement with tumor.
On the emotional level, these are just another two good articles nitpicking the cost of care of dying patients so that we can justify to some mindless managed "careaucrat" that we are providing the lowest cost of care possible for our patients, quality be damned. But bashing managed care is no longer fashionable. The new enemy on the horizon is the pharmaceutical industry. If you don't believe this, here is an excerpt from the Acting Editor-in-Chief of the New England Journal of Medicine in the June 22, 2000, issue: 3 ...Drug expenditures are now the fastest-growing component of health care costs, increasing at the rate of about 15 percent per year. They account for about 8 percent of health care spending, and at their current rate of increase, they will soon surpass spending for physicians' services and, for many health maintenance organizations (HMOs), the cost of hospitalization. The increase is due to both a greater use of drugs and to higher prices for individual drugs. Patients feel drug costs keenly, because they pay much of them out of pocket. Many private insurers tightly limit drug coverage, and Medicare does not cover outpatient drugs at all.
More to come on this issue!
